ÂÜÀòÂÒÂ×

Ron Guido is Chief Development Officer at Brooklyn ImmunoTherapeutics and was formerly Executive Vice President Regulatory Affairs and Quality Systems. He was previously Senior VP Regulatory Affairs and Quality Systems at IRX Therapeutics. Prior to joining the company in January 2017, Mr. Guido was Senior Vice-President Global Regulatory Affairs and Chief Compliance Officer for Veloxis Pharmaceuticals, Denmark. Mr. Guido was previously Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer. Ron Guido has held senior roles areas of preclinical screening, clinical research, regulatory affairs, product development and quality systems with Retrophin, V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth-Ayerst Laboratories. These responsibilities have included international and domestic regulatory affairs development programs encompassing drugs, devices, biologics, and nutritionals. Mr. Guido holds an M.S. in Technical Communications from the Polytechnic University, New York, and an MSc Pharmaceutical Medicine from Hibernia College, Dublin. He is currently Lecturer in Biology, in the Masters of Biotechnology Program at Columbia University of the City of New York.